Dergiler / Gülhane Tıp Dergisi / 2019 / Cilt: 61 - Sayı: 4

PCR-RFLP method enhance DNA sequencing of IDH1 somatic mutations detection in gliomas

Sayfa
167–171
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Thus, combination of DNA sequencing and PCR-RFLP method in heterogeneous glioma samples can be applied to avoid false negative result and cost-effective.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Aims:Isocitrate dehydrogenase 1 (IDH1) mutations are commonly found in lower grade gliomas and secondary GBMs.
📊
Temel Bulgular & Veri:Glioblastomas (GBMs) are the most common and most malignant gliomas in adult with a median survival of 15 months only.
💡
Sonuç & Katkı:Thus, combination of DNA sequencing and PCR-RFLP method in heterogeneous glioma samples can be applied to avoid false negative result and cost-effective.
🔬Tür:Araştırma Makalesi
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri

Özet

Aims:Isocitrate dehydrogenase 1 (IDH1) mutations are commonly found in lower grade gliomas and secondary GBMs. Glioblastomas (GBMs) are the most common and most malignant gliomas in adult with a median survival of 15 months only. Discovery of IDH1 mutations have made a significant positive impact on glioma patient’s diagnosis, prognosis, and treatments. Thus, IDH1 mutation screening method in gliomas is necessary to improve survival rate. The gold standard for somatic mutation screening, DNA sequencing was performed to detect IDH1 gene mutation status in glioma samples. Methods:Forty-seven formalin fixed paraffin-embedded glioma samples were subjected for DNA sequencing. The ambiguous glioma samples from DNA sequencing were subjected to PCR-RFLP for IDH1 mutation confirmation. Results:Three out of 47 glioma samples (6.4%) were found to harbor IDH1 mutations. Two IDH1 R132H and one IDH1 R132L were found in the glioma samples. From the DNA sequencing results, we found that the mutant nucleotide spectrum was lower than the wild-type nucleotide results in failure of IDH1 mutations detection. PCR-RFLP method was implemented to confirm the ambiguous IDH1 mutations. We found that the ambiguous IDH1 mutations from DNA sequencing were indeed IDH1 mutants using PCR-RFLP method. Conclusions:In conclusion, DNA sequencing method has a considerable low sensitivity level which leads to false negative results. Thus, combination of DNA sequencing and PCR-RFLP method in heterogeneous glioma samples can be applied to avoid false negative result and cost-effective.

🔖

Bu Makaleye Atıf Yap

GOH, W. C., IDRIS, B., KANDASAMY, R., SHAMSUDDIN, S., JAAFAR, H., AHMAD, F. (2019). PCR-RFLP method enhance DNA sequencing of IDH1 somatic mutations detection in gliomas. Gülhane Tıp Dergisi, Cilt: 61 - Sayı: 4, 167–171. https://ajindex.com/articles/160476

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (15)

  1. Donovan LE, Lassman AB. Chemotherapy Treatment and Trials in Low - Grade Gliomas. Neurosurgery Clinics of North America. 2019; 30(1):103–109
  2. Li S, Chou AP, Chen W, et al. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncology. 2013; 15(1):57–68
  3. Goh CH, Lu YY, Lau BL, et al. Brain and spinal tumour. Medical Journal Malaysia. 2014; 69(6):261–267
  4. Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing. Neuro Oncology. 2013; 15(6):718–726
  5. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807–1812
  6. Losman JA, Jr WGK. What a difference a hydroxyl makes: mutant IDH, ( R ) -2-hydroxyglutarate, and cancer. Genes Development. 2013; 27(8):836–852
  7. Liu A, Hou C, Chen H, Zong X, Zong P. Genetics and Epigenetics of Glioblastoma: Applications and Overall Incidence of IDH1 Mutation. Frontier Oncology. 2016; 6(16):1–9
  8. Ohgaki H, Kleihues P. The Definition of Primary and Secondary Glioblastoma. Clinical Cancer Research. 2013; 19(4):764–773
  9. Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: Implications for classification of gliomas. Acta Neuropathologica. 2010; 120(6):707–718
  10. Dang L, Yen K, Attar EC. IDH mutations in cancer and progress toward development of targeted therapeutics. Annals Oncology. 2016; 27(4):599–608
  11. Highsmith W. Electrophoretic Methods for Mutation Detection and DNA Sequencing.2nd ed. Humana Press;2006
  12. Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: A study of 1,010 diffuse gliomas. Acta Neuropathologica. 2009; 118(4):469–474
  13. Balss J, Meyer J, Mueller W, Korshunov A, Hartmann c, von Deimling A. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathologica. 2008;116(6):597–602
  14. Bleeker FE, Atai NA, Lamba S, et al. The prognostic IDH1R132 mutation is associated with reduced NADP+-dependent IDH activity in glioblastoma. Acta Neuropathologica. 2010; 119(4):487–494
  15. Aziz A, Yusoff M, Zulfakhar FN, Sul’ain MD, Idris Z, Abdullah JM. Association of The IDH1 C. 395G > A ( R132H ) Mutat